Navigation Links
PTC Therapeutics Announces Publication of Preclinical Data in PNAS
Date:2/4/2008

ng the premature stop signal and reading through the complete genetic instructions, resulting in the restoration of a full-length, functional protein. Patients with CF lack the CFTR protein, a chloride channel that maintains proper hydration of epithelial cells in the lung, pancreas, and liver. The data in PNAS demonstrate that PTC124 allows CFTR to be made in cells in which it was previously absent, to be delivered to the proper cellular location, and to induce chloride channel function. Collectively, these results indicate that this new approach may ultimately be applicable to a subset of patients across a large number of genetic disorders.

The paper entitled, "PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model," will be available in an advanced online publication of PNAS during the week of February 4, 2008 (http://www.pnas.org/papbyrecent.shtml). This publication is the result of collaborative efforts between the University of Alabama at Birmingham and PTC Therapeutics.

"These preclinical data further demonstrate the potential applicability of the PTC124 mechanism of action to multiple genetic disorders," said Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "We look forward to further evaluating PTC124 in registration-directed clinical trials in both CF and DMD this year, as well as in studies in additional genetic disorders in the future."

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely halt the translation process, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease m
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImaRx Therapeutics Transitions Business Strategy
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
4. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
5. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
8. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
9. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
10. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
11. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014 Today, DripDrop, the first great ... was awarded a two-year contract, effective Sept. 1, ... serves the more than 100,000 members and affiliates ... Provista.  DripDrop also received an ... hospitals who attended the recent Novation 2014 Innovative ...
(Date:10/30/2014)... NEW YORK , Oct. 29, 2014 /PRNewswire/ ... on the basis of test type, technology, product, ... to register the highest growth rate in the ... period. This high growth is attributed to various ... spectrometry is a fundamental instrument used for expanded ...
Breaking Medicine Technology:Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... SEATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Sciences, ... Phase III,AIR-CF2 study evaluating aztreonam lysine for ... (CF) who have,pulmonary Pseudomonas aeruginosa (P. aeruginosa). ... aztreonam lysine significantly improved,the time to need ...
... Demonstrated the Clinical Potential of Peregrine's,Unique Selective ... in Animal Cancer Models, TUSTIN, Calif., April ... a clinical stage,biopharmaceutical company developing targeted monoclonal ... C virus infection, today,reported that data from ...
Cached Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 PreDiabetes ... PreD Store shoppers with a supply of ... meals to reduce post-meal blood sugar spikes. Learning how ... is an important part of a diabetes prevention plan. ... will receive one complimentary tube of sugardown. The offer ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... October 30, 2014 Horse Sense ... horseback riding to special needs individuals in the Jacksonville ... Saturday, November 15 from 10-2:00 p.m. at Bailey's Farm ... open to the public and is designed to raise ... Admission to the HSS Round-Up is free. Ticket purchases ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2
... unreimbursed loss of as little as $500 would have ... As unemployment rates continue to climb, one often ... to affordable insurance. In a national recent survey conducted ... nearly two-thirds of respondents admitted to living paycheck-to-paycheck "often" ...
... Danaher Corporation (NYSE: DHR ... has approved a regular quarterly dividend of $0.03 ... holders of record on June 26, 2009.Danaher Corporation ... Technologies, Industrial Technologies and Tools and Components ( ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or ... , , , , ... , , , , , ... , , , , , ...
... (Nasdaq: ABAX ), a medical products company manufacturing ... operations officer, will present at the Bank of America and ... 2009 at 10:00 a.m. ET. The conference will be held ... invited to listen to a live audio webcast of the ...
... Ohio, May 7 STERIS Corporation (NYSE: STE ... a 38% increase in its quarterly dividend to $0.11 per ... to shareholders of record at the close of business on ... of STERIS Corporation is to provide a healthier today and ...
... Patient-Centered Primary Care Collaborative is the National ... ,Medical Home,WELLINGTON, Fla. May 7 The ... has joined the Executive Committee of the ... is a collaboration of major employers, consumer ...
Cached Medicine News:Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 2Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 3Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 2Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 4Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 5Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 6
Designated most popular model or size. Slightly angled, 2 mm wide....
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
... AMO Prestige System marked an amazing ... of safety with high-performance fluidics.A.S.E.T. keeps ... conditions in the in the anterior ... the reaction and interaction of the ...
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
Medicine Products: